


FORM PTO-1390 OFFICE		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK	ATTORNEY'S DOCKET NUMBER PF-0715 USN
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, see 37 CFR 1.5) TO BE ASSIGNED 10/030389
INTERNATIONAL APPLICATION NO. PCT/US00/18505	INTERNATIONAL FILING DATE 06 July 2000	PRIORITY DATE CLAIMED 06 July 1999	
TITLE OF INVENTION HUMAN IMMUNE RESPONSE MOLECULES			
APPLICANT(S) FOR DO/EO/US TANG, Y. Tom; YUE, Henry; YANG, Junming; AZIMZAI, Yalda; BAUGHN, Mariah R.; LU, Dyung Aina M.			
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <ol style="list-style-type: none"><input checked="" type="checkbox"/> This is the FIRST submission of items concerning a filing under 35 U.S.C. 371.<input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.<input type="checkbox"/> This is an express request to promptly begin national examination procedures (35 U.S.C. 371 (f)).<input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).<input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))<ol style="list-style-type: none"><input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau)<input type="checkbox"/> has been communicated by the International Bureau.<input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).<input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).<input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))<ol style="list-style-type: none"><input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).<input type="checkbox"/> have been communicated by the International Bureau.<input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.<input type="checkbox"/> have not been made and will not be made.<input checked="" type="checkbox"/> attached hereto Article 34 Amendment<input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).<input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).<input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).			
<p>Items 11 to 16 below concern document(s) or information included:</p> <ol style="list-style-type: none"><input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.<input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.27 and 3.31 is included.<input checked="" type="checkbox"/> A FIRST preliminary amendment, as follows: Cancel in this application original claims 14, 15, 18, 20, 21, 23, 24, 26, 27, 29 - 81 before calculating the filing fee, without prejudice or disclaimer. Applicants submit that these claims were included in the application as filed in the interest of providing notice to the public of certain specific subject matter intended to be claimed, and are being canceled at this time in the interest of reducing filing costs. Applicants expressly state that these claims are not being canceled for reasons related to patentability, and are in fact fully supported by the specification as filed. Applicants expressly reserve the right to reinstate these claims or to add other claims during prosecution of this application or a continuation or divisional application. Applicants expressly do not disclaim the subject matter of any invention disclosed herein which is not set forth in the instantly filed claims. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.<input type="checkbox"/> A substitute specification.<input type="checkbox"/> A change of power of attorney and/or address letter.<input checked="" type="checkbox"/> Other items or information:<ol style="list-style-type: none">Transmittal Letter (2 pp, in duplicate)Return PostcardExpress Mail Label No.: EL 856 146 927 USSequence Listing Statement			

U.S. APPLICATION NO. (if known) see 37 CFR 3.31 10/030389 TO BE ASSIGNED		INTERNATIONAL APPLICATION NO.: PCT/US00/18505		ATTORNEY'S DOCKET NUMBER PF-0715 USN	
17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO.....\$1000.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO..\$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$710.00 <input checked="" type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4).....\$710.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4).....\$100.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$710.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	20 =	0	X \$ 18.00	\$	
Independent Claims	2 =	0	X \$ 80.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	
SUBTOTAL =				\$710.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$710.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by the appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +					
TOTAL FEES ENCLOSED =				\$710.00	
				Amount to be Refunded:	\$
				Charged:	\$
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>09-0108</u> in the amount of <u>\$710.00</u> to cover the above fees. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>09-0108</u> . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
INCYTE GENOMICS, INC. 3160 Porter Drive Palo Alto, CA 94304			 SIGNATURE		
NAME: Diana Hamlet-Cox					
REGISTRATION NUMBER: 33,302					
DATE: <u>3</u> January 2002					

20020103 030389

"Express Mail" mailing label number EL 856 146 927 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Commissioner for Patents, Box Patent Application, Washington D.C. 20231 on 3 January 2002.

By: Nancy Ramos Printed: NANCY RAMOS
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Tang, et al.

Title: HUMAN IMMUNE RESPONSE MOLECULES

PCT Serial No.: PCT/US00/18505

International Filing Date: 06 July 2000

Examiner: To Be Assigned

Group Art Unit: To Be Assigned

Commissioner for Patents
BOX PATENT APPLICATION
Washington, D.C. 20231

REQUEST TO PUBLISH APPLICATION WITH ARTICLE 34 AMENDMENTS

Sir:

Applicants respectfully request that the present application be published under 35 U.S.C. § 122(b) with the claims as amended under PCT Article 34 on the attached substitute sheets, and which are submitted with the attached PCT application, rather than as originally filed.

Applicants submit that the Article 34 amendments should be considered as a part of the application as filed, as they were submitted in the form of replacement sheets during Chapter II examination of the PCT application, and should not be considered as a preliminary amendment which cannot be published unless submitted in electronic form.

Applicants believe that no fee is due with this communication. However, if the USPTO determines that a fee is due, the Commissioner is hereby authorized to charge Deposit Account No. **09-0108. This form is enclosed in duplicate.**

Respectfully submitted,

INCYTE GENOMICS, INC.

Diana Hamlet-Cox

Diana Hamlet-Cox

Reg. No. 33,302

Direct Dial Telephone: (650) 845-4639

Date: 3 January 2002

3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166

"Express Mail" mailing label number EL 892 011 750 US I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated and is addressed to: Commissioner for Patents, Box PCT, USPTO, P.O. Box 2327 Arlington, Virginia 22207 on 12-6-01.

By: Nancy RamosPrinted: Nancy RamosCHAPTER II

INTERNATIONAL EXAMINING AUTHORITY (IPEA/US)

PCT/US00/18505

INTERNATIONAL APPLICATION NO.

06 July 2000

INTERNATIONAL FILING DATE

06 July 1999

PRIORITY DATE CLAIMED

HUMAN IMMUNE RESPONSE MOLECULES

TITLE OF INVENTION

INCYTE GENOMICS, INC.

APPLICANT

United States Patent and Trademark Office
 P.O. Box PCT
 Washington, D.C. 20231

ARTICLE 34 AMENDMENT

Dear Sirs:

Please add new claims 29-81 in the above referenced international application as indicated below. A clean copy of the affected claims is attached (see pages 78/1-78/6). The replacement pages represent the new claims to be added as well as replacement page 78/1. These new claims do not go beyond the disclosure as filed.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: 05/Dec/2001Diana Hamlet-Cox

Diana Hamlet-Cox, Ph.D., Esq.

Reg. No. 33,302

Direct Dial Telephone: (650) 845-4639

Date: 12/10/2001Michelle M. Stempien

Michelle M. Stempien

Reg. No. 41,327

Direct Dial Telephone (650) 843-7219